CVS CVS Health

Q3 2025 10-Q

Filed: Oct 29, 2025Period ending Sep 30, 2025

Consumer Discretionary

Retail-Drug Stores and Proprietary StoresSEC EDGAR

CVS Health (CVS) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 29, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Management Discussion & Analysis

• No financial data or segment performance disclosed in the provided MD&A excerpt
• Forward-looking statements caution under Reform Act, no updated guidance or outlook given

+1 more insights

Risk Factors

• No material changes to risk factors compared to 10-K, risks carried forward without update
• COVID-19 pandemic impact on operations and supply chain remains significant near-term operational risk

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$102.9B

Net Income

-$4.0B

Operating Margin

-3.1%

Net Margin

-3.9%

ROE

-5.5%

Total Assets

$255.3B

Source: XBRL data from CVS Health Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other CVS Health Quarterly Reports

Q2 2025 10-Q

Q1 2025 10-Q

Get deeper insights on CVS Health

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.